Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company, announced its upcoming participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference. The company, which specializes in developing customizable, incision-free therapies for diseased tissue ablation, will present a business update on Tuesday, May 6, 2025, at 1:30 p.m. Eastern Time.
The presentation will take place at the Metro Toronto Convention Centre. Investors and interested parties can access the live broadcast and archived recording through the "Webcasts" section under Investors on the company's website at www.profoundmedical.com.
Profound Medical has announced groundbreaking results from their CAPTAIN trial, comparing TULSA procedure with robotic radical prostatectomy (RP) for prostate cancer treatment. The Level 1 study, involving 201 randomized patients across 23 sites, demonstrates significant advantages for TULSA.
Key findings show TULSA patients experienced:
- Zero blood loss compared to 100-200mL for RP
- 0.29 days hospital stay versus 1.24 days for RP
- Significantly lower post-operative pain through day 6
- Higher overall health scores for 30 days post-treatment
TULSA patients showed notably better outcomes in mobility (0% vs 12% extreme problems), self-care (3% vs 17%), and usual activities (17% vs 40%). The study included balanced patient characteristics, with median age ~63 years and similar PSA levels between groups. These results position TULSA as a potentially superior alternative to traditional prostate cancer surgery.
Profound Medical (NASDAQ: PROF; TSX: PRN), a commercial-stage medical device company focused on developing incision-free ablation therapies, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments from the period. Investors can access the live call through registration and the broadcast will be archived on the company's website under the Investors section.
Profound Medical Corp (NASDAQ:PROF) has announced details for its hybrid investor event scheduled for April 28, 2025, during the AUA Annual Meeting at the Waldorf Astoria in Las Vegas. The 90-minute event, running from 3:30-5:00 PM PT, will feature key presentations from company leadership and medical experts.
The agenda includes:
- Dr. Mathieu Burtnyk presenting CAPTAIN study results comparing TULSA to radical prostatectomy
- Dr. Ram Pathak sharing TULSA-PRO® clinical outcomes
- CEO Dr. Arun Menawat discussing TULSA-AI® for BPH and TULSA+ program with Siemens Healthineers
- Dr. Naveen Kella presenting on TULSA's BPH treatment capabilities
- CCO Tom Tamberrino outlining TULSA+ commercial strategy
The event will conclude with a Q&A session and will be available via webcast on the company's website.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN) has announced a hybrid investor event scheduled for April 28, 2025, during the American Urological Association (AUA) Annual Meeting in Las Vegas. The event will run from 3:30-5:00 PM PT (6:30-8:00 PM ET).
The program will feature presentations from both management and leading physicians, focusing on four key areas:
- TULSA-PRO® technology and its versatility in treating prostate disease patients
- Peri-operative results from the Level 1 CAPTAIN post-market study comparing TULSA procedure to radical prostatectomy
- Introduction of the new TULSA-AI® module for BPH, including a live technology demonstration
- Updates on the TULSA+ program, which integrates TULSA-PRO® with Siemens Healthineers' Magnetom Free.Max interventional MRI
Profound Medical (NASDAQ:PROF) reported strong Q4 2024 financial results with revenue reaching $4.2 million, marking a 108% increase compared to Q4 2023. The quarter saw $2.7 million from recurring revenue and $1.5 million from capital equipment sales.
Key Q4 highlights include executive changes with Mathieu Burtnyk promoted to President and Tom Tamberrino appointed as Chief Commercial Officer. The company entered a collaboration with Siemens Healthineers and launched the TULSA-AI® 'UA Alignment Assistant' module.
For full year 2024, revenue totaled $10.7 million, up from $7.2 million in 2023. The company reported a net loss of $27.8 million ($1.12 per share) compared to $28.3 million ($1.34 per share) in 2023. Operating expenses increased to $40.1 million from $33.0 million. As of December 31, 2024, Profound had cash of $54.9 million.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in incision-free ablation therapies for diseased tissue, has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.
The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments. The call will be accessible through online registration and will also be broadcast live and archived on the company's website under the Investors section.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in incision-free ablation therapies, announced a schedule change for its presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation has been moved to 9:00 a.m. Pacific Time on Thursday, January 16, 2025. Interested parties can access the live broadcast and archived recording through the 'Webcasts' section of the company's website at www.profoundmedical.com.